Beta Drugs Limited

NSEI:BETA 株式レポート

時価総額:₹20.6b

Beta Drugs バランスシートの健全性

財務の健全性 基準チェック /66

Beta Drugsの総株主資本は₹1.8B 、総負債は₹190.6Mで、負債比率は10.5%となります。総資産と総負債はそれぞれ₹2.9Bと₹1.1Bです。 Beta Drugsの EBIT は₹558.1Mで、利息カバレッジ比率27.2です。現金および短期投資は₹278.9Mです。

主要情報

10.5%

負債資本比率

₹190.60m

負債

インタレスト・カバレッジ・レシオ27.2x
現金₹278.87m
エクイティ₹1.81b
負債合計₹1.14b
総資産₹2.95b

財務の健全性に関する最新情報

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

財務状況分析

短期負債: BETAの 短期資産 ( ₹2.1B ) が 短期負債 ( ₹972.5M ) を超えています。

長期負債: BETAの短期資産 ( ₹2.1B ) が 長期負債 ( ₹164.0M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: BETA総負債よりも多くの現金を保有しています。

負債の削減: BETAの負債対資本比率は、過去 5 年間で32.5%から10.5%に減少しました。

債務返済能力: BETAの負債は 営業キャッシュフロー によって 十分にカバー されています ( 132.1% )。

インタレストカバレッジ: BETAの負債に対する 利息支払いEBIT ( 27.2 x coverage) によって 十分にカバーされています


貸借対照表


健全な企業の発掘